Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMP-17 by Eikon Therapeutics for Solid Tumor: Likelihood of Approval
IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
IMP-17 by Eikon Therapeutics for Peritoneal Cancer: Likelihood of Approval
IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
IMP-17 by Eikon Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
IMP-17 by Eikon Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
IMP-17 by Eikon Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
IMP-17 by Eikon Therapeutics for Ovarian Cancer: Likelihood of Approval
IMP-17 is under clinical development by Eikon Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
BDB-001 by Eikon Therapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
BDB-001 is under clinical development by Eikon Therapeutics and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According...